Evaluación de la Respuesta patológica a la terapia neoadyuvante en pacientes con Cáncer de Mama tratadas en ONCOSERV
Year: 2025
Type: article
Study design: Observational Study
Abstract: Introduction: Pathological complete response (pCR) following neoadjuvant therapy in breast cancer is a key prognostic marker associated with improved survival. However, in the Dominican Republic, data on factors associated with pCR remain limited. This study eval-uates the frequency of pCR and its associated factors in patients treated at ONCOSERV. Methods: We conducted an observational, retrospective, and analyt-ical cross-sectional study based on medical records of breast cancer patients who underwent neoadjuvant therapy between 2021 and 2023. Sociodemographic, clinical, and therapeutic variables were analyzed. Logistic regression models were used to assess associa-tions with pCR. Results: A total of 110 patients were included, with a pCR rate of 30%. The probability of pCR was lower in patients with advanced clinical stages (OR=0.287; 95% CI: 0.117-0.637; p=0.004) and those with poorer functional status (OR=0.281; 95% CI: 0.089-0.738; p=0.017). pCR was more frequent in patients with HER2+/HR+ tumors (OR=4.373; 95% CI: 1.141-17.970; p=0.034). A diagnostic delay of more than five weeks significantly reduced pCR in patients with advanced stages (OR=0.066; 95% CI: 0.010-0.350; p=0.002) and those with subsidized health insurance (OR=0.158; 95% CI: 0.026-0.874; p=0.037). Conclusions: Clinical stage, functional status, molecular profile, educational level, and health insurance type influence pCR. Diagnostic delays nega-tively impact treatment response, underscoring the need for strategie
Authors: Prestol Puesan, Rogelio Salvador, Báez Jiménez, Marien, Baldera, Jonathan Patricio
Institution: Universidad Autónoma de Santo Domingo
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7082094979
